 |
 Video: What is a Stock Split?
|
|
|
| Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Co.'s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare monogenic muscle disease. Co. pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy. According to our Avidity Biosciences stock split history records, Avidity Biosciences has had 0 splits. | |
|
Avidity Biosciences (RNA) has 0 splits in our Avidity Biosciences stock split history database.
Looking at the Avidity Biosciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Avidity Biosciences shares, starting with a $10,000 purchase of RNA, presented on a split-history-adjusted basis factoring in the complete Avidity Biosciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/12/2020 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$28.50 |
|
| End price/share: |
$25.09 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-11.96% |
|
| Average Annual Total Return: |
-3.24% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$8,803.69 |
|
| Years: |
3.87 |
|
|
|
|
|
